Gene therapy for human alpha1-antitrypsin deficiency in an animal model using SV40-derived vectors.
Gastroenterology
; 127(4): 1222-32, 2004 Oct.
Article
em En
| MEDLINE
| ID: mdl-15480999
ABSTRACT
BACKGROUND & AIMS:
In most genetic diseases, the goal of gene therapy is to deliver a particular transgene; however, sometimes a deleterious gene product must be eliminated. Because of the promise of recombinant simian virus 40 (rSV40) vectors, we tested their ability to deliver a transgene and to target a transcript for destruction by direct administration of the vectors to the liver of an animal model for human alpha1-antitrypsin (alpha1-AT) deficiency.METHODS:
Therapy of human alpha1-AT deficiency requires stable transduction of resting hepatocytes, both to deliver wild-type alpha1-AT and to inhibit production of mutant alpha1-AT. Transgenic mice carrying the mutant human alpha1-AT PiZ allele were treated through an indwelling portal vein catheter with a simian virus 40 (SV40)-derived vector carrying a ribozyme designed to target the human transcript.RESULTS:
Treated transgenic mice showed marked decreases of human alpha1-AT messenger RNA and the protein in the liver, and serum levels of human alpha1-AT were decreased to 50% +/- 5% of pretreatment values 3-16 weeks after transduction. Moreover, when normal mice were treated with an SV40-derived vector containing a modified human alpha1-AT complementary DNA engineered to be resistant to cleavage by the alpha1-AT ribozyme, they expressed human alpha1-AT messenger RNA and protein in their livers and serum levels of human alpha1-AT remained >1 microg/mL for 1 year.CONCLUSIONS:
These results represent the initial steps toward a novel approach to the gene therapy of alpha1-AT deficiency.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Terapia Genética
/
Alfa 1-Antitripsina
/
RNA Catalítico
/
Vírus 40 dos Símios
/
Deficiência de alfa 1-Antitripsina
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Gastroenterology
Ano de publicação:
2004
Tipo de documento:
Article
País de afiliação:
Estados Unidos